跳至主要内容
临床试验/CTRI/2025/12/099280
CTRI/2025/12/099280尚未招募不适用

A Prospective Observational study to assess the Impact of Treatment Interruption on disease outcome in Head and Neck Squamous Cell Carcinoma treated with Concomitant Chemo- Radiotherapy.

Shreshth Vinaik1 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2025年12月27日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
96
试验地点
1
主要终点
To determine the Impact of Treatment Interruption on overall disease response and Progression Free Survival of patients treated with Concomitant Chemo-Radiotherapy for Head and Neck Squamous Cell Carcinoma.

研究概览

简要总结

The outcome We plan to reach with this research is to best find the impact of prolonged overall treatment time due to treatment interruptions in a planned RT schedule of HNSCC patients on the overall response and  disease progression of the patients. We expect by this study to see that a delay in treatment will lead to poor outcomes in the patients. The poor outcomes that are caused by such RT delays in our setting will serve as a suggestion to find out the causes and remedy them, especially the easily avoidable factors.

研究设计

研究类型
Observational

入排标准

年龄范围
20.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Patients willing to participate in the study by giving written consent.
  • Histopathologically proven Head and Neck Squamous cell carcinoma C.
  • Follows AJCC TNM Staging: will include T3 and T4 stages and/or N1-3 and M0 D.
  • Adult patient (20 years to 70 years) E.
  • Performance status (ECOG 0-2) F.
  • Normal haematological parameters at the time of start of the treatment: Haemoglobin more than 10 gm/dL, Absolute Neutrophil Count (ANC) more than 1500/cu.mm., Platelet count more than 1L/cu.mm.
  • Normal biochemical blood parameters like Liver function test and Renal function test: Liver enzymes (ALT/AST) less than 3UNL, Est.
  • Creatinine Clearance more than 50 H.
  • Patient willing to come for follow up.

排除标准

  • Carcinoma of the Nasopharynx
  • Patients requiring Neoadjuvant Chemotherapy
  • Comorbidities, unrelated to the disease in study
  • Prior treatment with radiotherapy or surgery with curative intent for the disease under study/ Recurrent disease
  • Any second primary or other malignancies within the last 5 years
  • Pregnant patients.

结局指标

主要结局

To determine the Impact of Treatment Interruption on overall disease response and Progression Free Survival of patients treated with Concomitant Chemo-Radiotherapy for Head and Neck Squamous Cell Carcinoma.

时间窗: 3 weeks, 3 months, and then 3 monthly follow ups

次要结局

  • To find out the factors causing treatment interruption in Head & Neck Squamous Cell Carcinoma patient on Concomitant Chemo-Radiotherapy(End of Treatment ie after the 45 day long standard Radiation Regime)

研究者

发起方
Shreshth Vinaik
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Shreshth Vinaik

Institute of Post Graduate Medical Education and Research Kolkata

研究点 (1)

Loading locations...

相似试验